» Articles » PMID: 10816477

Local Anticandidal Immune Responses in a Rat Model of Vaginal Infection by and Protection Against Candida Albicans

Overview
Journal Infect Immun
Date 2000 May 19
PMID 10816477
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Humoral (antibody [Ab]) and cellular Candida-specific immune responses in the vaginas of pseudoestrus rats were investigated during three successive infections by Candida albicans. After the first, protective infection, Abs against mannan and aspartyl proteinase antigens were present in the vaginal fluid, and their titers clearly increased during the two subsequent, rapidly healing infections. In all animals, about 65 and 10% of vaginal lymphocytes (VL) were CD3(+) (T cells) and CD3(-) CD5(+) (B cells), respectively. Two-thirds of the CD3(+) T cells expressed the alpha/beta and one-third expressed the gamma/delta T-cell receptor (TCR). This proportion slightly fluctuated during the three rounds of C. albicans infection, but no significant differences between infected and noninfected rats were found. More relevant were the changes in the CD4(+)/CD8(+) T-cell ratio, particularly for cells bearing the CD25 (interleukin-2 receptor alpha) marker. In fact, a progressively increased number of both CD4(+) alpha/beta TCR and CD4(+) CD25(+) VL was observed after the second and third Candida challenges, reversing the high initial CD8(+) cell number of controls (estrogenized but uninfected rats). The CD3(-) CD5(+) cells also almost doubled from the first to the third infection. Analysis of the cytokines secreted in the vaginal fluid of Candida-infected rats showed high levels of interleukin 12 (IL-12) during the first infection, followed by progressively increasing amounts of IL-2 and gamma interferon during the subsequent infections. No IL-4 or IL-5 was ever detected. During the third infection, VL with in vitro proliferative activity in response to an immunodominant mannoprotein antigen of C. albicans were present in the vaginal tissue. No response to this antigen by mitogen-responsive blood, lymph node, and spleen cells was found. In summary, the presence of protective Ab and T helper type 1 cytokines in the vaginal fluids, the in vitro proliferation of vaginal lymphocytes in response to Candida antigenic stimulation, and the increased number of activated CD4(+) cells and some special B lymphocytes after C. albicans challenge constitute good evidence for induction of locally expressed Candida-specific Ab and cellular responses which are potentially involved in anticandidal protection at the vaginal level.

Citing Articles

Bioactive Potential of Chitosan-Oleic Acid Nanoparticles Loaded with Lemon Peel Essential Oil for Topical Treatment of Vulvovaginal Candidiasis.

Ibrahim F, Shalaby E, Abdelhameed M, El-Akad R, Ahmed K, Abdel-Aziz M Molecules. 2024; 29(23).

PMID: 39683923 PMC: 11643761. DOI: 10.3390/molecules29235766.


Comparing the therapeutic potentials of vs. against vulvovaginal candidiasis in female rats: an study.

ElFeky D, Awad A, ShamsEldeen A, Mowafy H, Hosny S Front Microbiol. 2023; 14:1222503.

PMID: 37529322 PMC: 10388188. DOI: 10.3389/fmicb.2023.1222503.


Lab-Based Retrospective 10-Year Analysis Shows Seasonal Variation of Vaginal Infection Rates in Belgium.

Donders G, Ruban K, Donders F, Reybrouck R J Clin Med. 2022; 11(3).

PMID: 35160026 PMC: 8836942. DOI: 10.3390/jcm11030574.


The Role of B-Cells and Antibodies against Vaccine Antigens in Invasive Candidiasis.

Shukla M, Chandley P, Rohatgi S Vaccines (Basel). 2021; 9(10).

PMID: 34696267 PMC: 8540628. DOI: 10.3390/vaccines9101159.


Formulation and Characterization of Sertaconazole Nitrate Mucoadhesive Liposomes for Vaginal Candidiasis.

Abdellatif M, Khalil I, Elakkad Y, Eliwa H, Samir T, Al-Mokaddem A Int J Nanomedicine. 2020; 15:4079-4090.

PMID: 32606665 PMC: 7295534. DOI: 10.2147/IJN.S250960.


References
1.
Fidel Jr P, Luo W, Chabain J, Wolf N, VAN BUREN E . Use of cellular depletion analysis to examine circulation of immune effector function between the vagina and the periphery. Infect Immun. 1997; 65(9):3939-43. PMC: 175562. DOI: 10.1128/iai.65.9.3939-3943.1997. View

2.
De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G, Cassone A . Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun. 1997; 65(8):3399-405. PMC: 175481. DOI: 10.1128/iai.65.8.3399-3405.1997. View

3.
Blank K, Sieck T . Genetic basis for protection against experimental vaginal candidiasis by peripheral immunization. J Infect Dis. 1998; 178(1):227-34. DOI: 10.1086/515602. View

4.
Elitsur Y, Jackman S, Neace C, Keerthy S, Liu X, Dosescu J . Human vaginal mucosal immune system: characterization and function. Gen Diagn Pathol. 1998; 143(5-6):271-7. View

5.
Han Y, Morrison R, Cutler J . A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun. 1998; 66(12):5771-6. PMC: 108729. DOI: 10.1128/IAI.66.12.5771-5776.1998. View